Bioventus (NASDAQ:BVS) Trading Down 6.3% – Time to Sell?

Bioventus Inc. (NASDAQ:BVS) fell 6.3% during mid-day trading on Thursday . The company traded as low as $9.91 and last traded at $10.2530. 90,046 shares were traded during trading, a decline of 76% from the average session volume of 382,108 shares. The stock had previously closed at $10.94.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BVS. CJS Securities began coverage on shares of Bioventus in a research note on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price for the company. Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Barrington Research raised their target price on shares of Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Finally, Craig Hallum raised their target price on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $14.00.

Bioventus Trading Down 11.1%

The stock’s fifty day simple moving average is $9.64 and its 200-day simple moving average is $8.45. The firm has a market cap of $812.43 million, a PE ratio of 23.63, a PEG ratio of 1.36 and a beta of 0.72. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. The business had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts forecast that Bioventus Inc. will post 0.79 earnings per share for the current year.

Insider Activity

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of the firm’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the transaction, the director owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BVS. Caitong International Asset Management Co. Ltd raised its holdings in shares of Bioventus by 17,156.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after buying an additional 5,490 shares during the last quarter. Covestor Ltd grew its position in Bioventus by 28.0% during the 3rd quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after purchasing an additional 2,176 shares during the period. Olympiad Research LP acquired a new stake in Bioventus during the 3rd quarter worth about $74,000. Prelude Capital Management LLC purchased a new position in Bioventus in the third quarter valued at $74,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Bioventus in the third quarter valued at $78,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.